LM-317 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

LM317 - Ethics in Action: Navigating Gray Areas (AAA 2026) - "• Upon completion, participants will be able to utilize a systematic decision-making process to address ethical challenges in clinical practice. • Upon completion, participants will be able to identify and evaluate potential courses of action for resolving ethical dilemmas."

Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b (AACR 2024) - "The novel ADC LM-317 targeting NaPi2b showed robust antitumor activity in vitro, and in the OC and NSCLC cell line derived models and PDX models. LM-317 could potentially provide therapeutic benefit to treat NaPi2b-positive tumors including OC and NSCLC in the future.Reference: 1.S. Banerjee et al."

ADC • Preclinical • Endocrine Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • SLC34A2